What is AGIO's current stock price?

AGIO (Agios Pharmaceuticals, Inc.) is currently trading at $28.14 with a market cap of $1.67B.

What sector is Agios Pharmaceuticals, Inc. in?

Agios Pharmaceuticals, Inc. (AGIO) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AGIO a good stock to buy?

Analysts have a Buy consensus on AGIO with a price target of $42.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AGIO Agios Pharmaceuticals, Inc.

Healthcare

$28.14-2.26%ClosedMarket Cap: $1.67B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.49

P/S

25.34

EV/EBITDA

-3.39

DCF Value

$-26.44

FCF Yield

-23.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

82.1%

Operating Margin

-720.0%

Net Margin

-639.8%

ROE

-34.1%

ROA

-35.7%

ROIC

-41.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$20.7M	$-99.1M	$—
Q4 null	$20.0M	$-108.0M	$—
FY null	$54.0M	$-412.8M	$—
Q3 null	$12.9M	$-103.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$42.00

Target (Median)

$40.00

Target Range

$36.00 - $50.00

0 Strong Buy7 Buy3 Hold0 Sell0 Strong Sell

Truist SecuritiesBuy

2026-04-30

B of A SecuritiesBuy

2026-04-21

HC Wainwright & Co.Buy

2026-04-20

JP MorganNeutral

2026-04-06

Goldman SachsNeutral

2026-04-01

Trading Activity

Insider Trades

View All

Milanova Tsvetaofficer: Chief Commercial Officer

SellMon Apr 06

Jones Ceciliaofficer: Chief Financial Officer

SellMon Apr 06

Jones Ceciliaofficer: Chief Financial Officer

SellMon Apr 06

Gheuens Sarahofficer: Chief Medical Officer

SellMon Apr 06

Gheuens Sarahofficer: Chief Medical Officer

SellMon Apr 06

Congress Trades

View All

Gilbert CisnerosBuy

Wed Apr 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.58

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Peers